T1	PROC 1184 1197	Aleatorizamos
#1	AnnotatorNotes T1	C0034656; Randomization; Research Activity
T2	CHEM 23 34	calcifediol
#2	AnnotatorNotes T2	C0006657; calcifediol; Vitamin · Pharmacologic Substance
T3	CHEM 46 58	paricalcitol
#3	AnnotatorNotes T3	C0249582; paricalcitol; Organic Chemical · Vitamin · Pharmacologic Substance
T4	ANAT 85 99	cardiovascular
#4	AnnotatorNotes T4	C0007226; Cardiovascular system; Body System | C3887460; Cardiovascular; Body Location or Region
T5	PROC 103 115	hemodiálisis
#5	AnnotatorNotes T5	C0019004; Hemodialysis; Therapeutic or Preventive Procedure
T6	CHEM 2270 2275	25OHD
#6	AnnotatorNotes T6	C0535968; 25-hydroxyvitamin D; Organic Chemical · Vitamin
T7	DISO 188 218	hiperparatiroidismo secundario
#7	AnnotatorNotes T7	C0020503; Hyperparathyroidism, Secondary; Disease or Syndrome
T8	PROC 2201 2229	homeostasis model assessment
#8	AnnotatorNotes T8	C1829779; Homeostasis model assessment; Health Care Activity
T9	DISO 261 285	enfermedad renal crónica
#9	AnnotatorNotes T9	C0403447; Chronic Kidney Insufficiency; Disease or Syndrome | C1561643; Chronic Kidney Diseases; Disease or Syndrome
T10	DISO 287 290	ERC
#10	AnnotatorNotes T10	C0403447; Chronic Kidney Insufficiency; Disease or Syndrome | C1561643; Chronic Kidney Diseases; Disease or Syndrome
T11	PROC 295 307	hemodiálisis
#11	AnnotatorNotes T11	C0019004; Hemodialysis; Therapeutic or Preventive Procedure
T12	CHEM 167 172	25OHD
#12	AnnotatorNotes T12	C0535968; 25-hydroxyvitamin D; Organic Chemical · Vitamin
T13	ANAT 388 402	cardiovascular
#13	AnnotatorNotes T13	C0007226; Cardiovascular system; Body System | C3887460; Cardiovascular; Body Location or Region
T14	ANAT 404 406	CV
#14	AnnotatorNotes T14	C0007226; Cardiovascular system; Body System | C3887460; Cardiovascular; Body Location or Region
T15	ANAT 417 424	séricos
#15	AnnotatorNotes T15	C0229671; Serum; Body Substance | C0588987; Serum product; Body Substance
T16	CHEM 464 513	activadores selectivos del receptor de vitamina D
T17	PROC 1915 1920	Pinp1
T18	ANAT 586 590	óseo
#16	AnnotatorNotes T18	C0262950; Skeletal bone; Body Part, Organ, or Organ Component | C0391978; Bone Tissue; Tissue
T19	CHEM 591 598	mineral
#17	AnnotatorNotes T19	C0026162; Minerals; Inorganic Chemical
T20	ANAT 611 613	CV
#18	AnnotatorNotes T20	C0007226; Cardiovascular system; Body System | C3887460; Cardiovascular; Body Location or Region
T21	DISO 741 744	ERC
#19	AnnotatorNotes T21	C0403447; Chronic Kidney Insufficiency; Disease or Syndrome | C1561643; Chronic Kidney Diseases; Disease or Syndrome
T22	CHEM 864 869	25OHD
#20	AnnotatorNotes T22	C0535968; 25-hydroxyvitamin D; Organic Chemical · Vitamin
T23	PROC 1804 1833	marcadores de remodelado óseo
#21	AnnotatorNotes T23	C1869108; Biochemical markers of bone metabolism; Research Activity (?)
T24	PROC 839 860	tratamiento combinado
#22	AnnotatorNotes T24	C0009429; Combined Modality Therapy; Therapeutic or Preventive Procedure
T25	CHEM 871 882	calcifediol
#23	AnnotatorNotes T25	C0006657; calcifediol; Vitamin · Pharmacologic Substance
T26	ANAT 936 940	óseo
#24	AnnotatorNotes T26	C0262950; Skeletal bone; Body Part, Organ, or Organ Component | C0391978; Bone Tissue; Tissue
T27	CHEM 897 909	paricalcitol
#25	AnnotatorNotes T27	C0249582; paricalcitol; Organic Chemical · Vitamin · Pharmacologic Substance
T28	CHEM 890 895	AsRVD
T29	CHEM 941 948	mineral
#26	AnnotatorNotes T29	C0026162; Minerals; Inorganic Chemical
T30	DISO 962 975	inflamatorios
#27	AnnotatorNotes T30	C0021368; Inflammation; Pathologic Function
T31	PROC 989 1000	tratamiento
#28	AnnotatorNotes T31	C0087111; Therapeutic procedure; Therapeutic or Preventive Procedure
T32	PROC 1328 1335	tratado
#29	AnnotatorNotes T32	C0087111; Therapeutic procedure; Therapeutic or Preventive Procedure
T33	PROC 1097 1116	estudio prospectivo
#30	AnnotatorNotes T33	C0033522; Prospective Studies; Research Activity
T34	PROC 1746 1751	25OHD
#31	AnnotatorNotes T34	C2984945; 25-Hydroxyvitamin D Measurement; Laboratory Procedure
T35	PROC 1253 1264	tratamiento
#32	AnnotatorNotes T35	C0087111; Therapeutic procedure; Therapeutic or Preventive Procedure
T36	CHEM 1340 1351	calcifediol
#33	AnnotatorNotes T36	C0006657; calcifediol; Vitamin · Pharmacologic Substance
T37	PROC 1430 1441	tratamiento
#34	AnnotatorNotes T37	C0087111; Therapeutic procedure; Therapeutic or Preventive Procedure
T38	CHEM 1462 1473	calcifediol
#35	AnnotatorNotes T38	C0006657; calcifediol; Vitamin · Pharmacologic Substance
T39	CHEM 1483 1495	paricalcitol
#36	AnnotatorNotes T39	C0249582; paricalcitol; Organic Chemical · Vitamin · Pharmacologic Substance
T40	PROC 1535 1547	tratamientos
#37	AnnotatorNotes T40	C0087111; Therapeutic procedure; Therapeutic or Preventive Procedure
T41	PROC 1600 1611	seguimiento
#38	AnnotatorNotes T41	C1522577; Follow up; Health Care Activity | C0420316; Other follow-up; Health Care Activity
T42	PROC 1617 1643	determinaciones analíticas
T43	ANAT 1735 1742	séricos
#39	AnnotatorNotes T43	C0229671; Serum; Body Substance | C0588987; Serum product; Body Substance
T44	PROC 1927 1977	telopéptido carboxilo-terminal del colágeno tipo I
T45	PROC 1992 2016	marcadores inflamatorios
#40	AnnotatorNotes T45	C3805088; Inflammatory marker test; Laboratory Procedure
T46	PROC 2118 2141	agentes eritropoyéticos
T47	PROC 2143 2146	AEE
T48	ANAT 1829 1833	óseo
#41	AnnotatorNotes T48	C0262950; Skeletal bone; Body Part, Organ, or Organ Component | C0391978; Bone Tissue; Tissue
T49	PROC 1846 1864	fosfatasa alcalina
#42	AnnotatorNotes T49	C0201850; Alkaline phosphatase measurement; Laboratory Procedure
T50	PROC 1866 1913	propéptido aminoterminal del procolágeno tipo 1
T51	PROC 2195 2199	HOMA
#43	AnnotatorNotes T51	C1829779; Homeostasis model assessment; Health Care Activity
T52	PROC 2150 2192	índices de resistencia a la eritropoyetina
T53	PROC 1 12	Tratamiento
#44	AnnotatorNotes T53	C0087111; Therapeutic procedure; Therapeutic or Preventive Procedure
T54	DISO 2003 2016	inflamatorios
#45	AnnotatorNotes T54	C0021368; Inflammation; Pathologic Function
T55	PROC 2018 2033	interleuquina 8
#46	AnnotatorNotes T55	C4700790; interleukin-8 in serum or plasma; Laboratory Procedure
T56	PROC 2035 2039	IL-8
#47	AnnotatorNotes T56	C4700790; interleukin-8 in serum or plasma; Laboratory Procedure
T57	CHEM 2086 2094	insulina
#48	AnnotatorNotes T57	C0021641; Insulin; Amino Acid, Peptide, or Protein · Hormone · Pharmacologic Substance | C3537244; Insulins; Pharmacologic Substance
T58	PROC 2096 2103	glucosa
#49	AnnotatorNotes T58	C0337438; Glucose measurement; Laboratory Procedure
T59	PROC 2811 2830	marcador óseo Pinp1
#50	AnnotatorNotes T59	C1869108; Biochemical markers of bone metabolism; Research Activity (?) | C1562880; Procollagen type I amino-terminal propeptide level; Laboratory Procedure
T60	PROC 2952 2963	tratamiento
#51	AnnotatorNotes T60	C0087111; Therapeutic procedure; Therapeutic or Preventive Procedure
T61	CHEM 2178 2192	eritropoyetina
#52	AnnotatorNotes T61	C0014822; Erythropoietin; Amino Acid, Peptide, or Protein · Hormone · Pharmacologic Substance
T62	CHEM 2369 2380	calcifediol
#53	AnnotatorNotes T62	C0006657; calcifediol; Vitamin · Pharmacologic Substance
T63	DISO 2432 2441	toxicidad
#54	AnnotatorNotes T63	C0600688; Toxic effect; Injury or Poisoning
T64	PROC 2536 2547	tratamiento
#55	AnnotatorNotes T64	C0087111; Therapeutic procedure; Therapeutic or Preventive Procedure
T65	PROC 3086 3107	marcador inflamatorio
#56	AnnotatorNotes T65	C3805088; Inflammatory marker test; Laboratory Procedure
T66	PROC 2599 2613	niveles de PTH
#57	AnnotatorNotes T66	C0202159; Parathyroid hormone measurement; Laboratory Procedure
T67	PROC 2710 2713	PTH
#58	AnnotatorNotes T67	C0202159; Parathyroid hormone measurement; Laboratory Procedure
T68	CHEM 3168 3171	AEE
#59	AnnotatorNotes T68	C1959590; Erythropoiesis Stimulating Agents; Pharmacologic Substance
T69	ANAT 2820 2824	óseo
#60	AnnotatorNotes T69	C0262950; Skeletal bone; Body Part, Organ, or Organ Component | C0391978; Bone Tissue; Tissue
T70	CHEM 2836 2848	paricalcitol
#61	AnnotatorNotes T70	C0249582; paricalcitol; Organic Chemical · Vitamin · Pharmacologic Substance
T71	PROC 3455 3465	marcadores
#62	AnnotatorNotes T71	C3805088; Inflammatory marker test; Laboratory Procedure
T72	ANAT 2916 2929	células óseas
#63	AnnotatorNotes T72	C0222677; Cell of bone; Cell
T73	CHEM 2989 3001	paricalcitol
#64	AnnotatorNotes T73	C0249582; paricalcitol; Organic Chemical · Vitamin · Pharmacologic Substance
T74	CHEM 3059 3063	IL-8
#65	AnnotatorNotes T74	C0079633; interleukin-8; Immunologic Factor · Amino Acid, Peptide, or Protein
T75	DISO 3095 3107	inflamatorio
#66	AnnotatorNotes T75	C0021368; Inflammation; Pathologic Function
T76	DISO 3217 3228	inflamación
#67	AnnotatorNotes T76	C0021368; Inflammation; Pathologic Function
T77	CHEM 3355 3366	calcifediol
#68	AnnotatorNotes T77	C0006657; calcifediol; Vitamin · Pharmacologic Substance
T78	CHEM 3367 3379	paricalcitol
#69	AnnotatorNotes T78	C0249582; paricalcitol; Organic Chemical · Vitamin · Pharmacologic Substance
T79	CHEM 3475 3487	Paricalcitol
#70	AnnotatorNotes T79	C0249582; paricalcitol; Organic Chemical · Vitamin · Pharmacologic Substance
T80	DISO 134 165	déficit de 25-hidroxivitamina D
T81	ANAT 272 277	renal
#71	AnnotatorNotes T81	C0022646; Kidney; Body Part, Organ, or Organ Component | C1278978; Entire kidney; Body Part, Organ, or Organ Component
T82	PROC 309 311	HD
#72	AnnotatorNotes T82	C0019004; Hemodialysis; Therapeutic or Preventive Procedure
T83	CHEM 515 520	AsRVD
T84	DISO 604 613	riesgo CV
#73	AnnotatorNotes T84	C4324389; Cardiovascular Risk; Finding
T85	PROC 748 750	HD
#74	AnnotatorNotes T85	C0019004; Hemodialysis; Therapeutic or Preventive Procedure
T86	PROC 1058 1060	HD
#75	AnnotatorNotes T86	C0019004; Hemodialysis; Therapeutic or Preventive Procedure
T87	PROC 1180 1182	HD
#76	AnnotatorNotes T87	C0019004; Hemodialysis; Therapeutic or Preventive Procedure
T88	CHEM 1269 1281	paricalcitol
#77	AnnotatorNotes T88	C0249582; paricalcitol; Organic Chemical · Vitamin · Pharmacologic Substance
T89	PROC 3048 3063	niveles de IL-8
#78	AnnotatorNotes T89	C4700790; interleukin-8 in serum or plasma; Laboratory Procedure
T90	PROC 1753 1759	calcio
#79	AnnotatorNotes T90	C0201925; Calcium measurement; Laboratory Procedure
T91	PROC 1761 1768	fósforo
#80	AnnotatorNotes T91	C0202178; Phosphorus measurement; Laboratory Procedure
T92	PROC 1771 1791	hormona paratiroidea
#81	AnnotatorNotes T92	C0202159; Parathyroid hormone measurement; Laboratory Procedure
T93	PROC 1793 1796	PTH
#82	AnnotatorNotes T93	C0202159; Parathyroid hormone measurement; Laboratory Procedure
T94	PROC 2075 2094	niveles de insulina
#83	AnnotatorNotes T94	C0202098; Insulin measurement; Laboratory Procedure
T95	PROC 2105 2116	hemoglobina
#84	AnnotatorNotes T95	C0518015; Hemoglobin measurement; Laboratory Procedure
T96	DISO 2259 2275	déficit de 25OHD
#85	AnnotatorNotes T96	C0042870; Vitamin D Deficiency; Disease or Syndrome
T97	PROC 2350 2364	suplementación
#86	AnnotatorNotes T97	C0242297; Dietary Supplementation; Therapeutic or Preventive Procedure
T98	DISO 2407 2414	déficit
#87	AnnotatorNotes T98	C0042870; Vitamin D Deficiency; Disease or Syndrome
T99	CHEM 2552 2564	paricalcitol
#88	AnnotatorNotes T99	C0249582; paricalcitol; Organic Chemical · Vitamin · Pharmacologic Substance
T100	CHEM 2610 2613	PTH
#89	AnnotatorNotes T100	C0020063; PTH protein, human; Amino Acid, Peptide, or Protein · Hormone | C0030520; parathyroid hormone; Amino Acid, Peptide, or Protein · Hormone · Pharmacologic Substance
T101	CHEM 2968 2979	calcifediol
#90	AnnotatorNotes T101	C0006657; calcifediol; Vitamin · Pharmacologic Substance
T102	PROC 3233 3244	índice HOMA
#91	AnnotatorNotes T102	C1829779; Homeostasis model assessment; Health Care Activity
T103	ANAT 3559 3563	ósea
#92	AnnotatorNotes T103	C0262950; Skeletal bone; Body Part, Organ, or Organ Component | C0391978; Bone Tissue; Tissue
T104	DISO 78 99	riesgo cardiovascular
#93	AnnotatorNotes T104	C4324389; Cardiovascular Risk; Finding
T105	CHEM 145 165	25-hidroxivitamina D
#94	AnnotatorNotes T105	C0535968; 25-hydroxyvitamin D; Organic Chemical · Vitamin
T106	CHEM 438 443	25OHD
#95	AnnotatorNotes T106	C0535968; 25-hydroxyvitamin D; Organic Chemical · Vitamin
T107	PROC 695 709	suplementación
#96	AnnotatorNotes T107	C0242297; Dietary Supplementation; Therapeutic or Preventive Procedure
T108	PROC 951 975	marcadores inflamatorios
#97	AnnotatorNotes T108	C3805088; Inflammatory marker test; Laboratory Procedure
T109	LIVB 247 256	pacientes
#98	AnnotatorNotes T109	C0030705; Patients; Patient or Disabled Group
T110	Duration 278 285	crónica
#99	AnnotatorNotes T110	C0205191; chronic; Temporal Concept
T111	PHYS 574 598	metabolismo óseo-mineral
#100	AnnotatorNotes T111	C0596204; bone metabolism; Organ or Tissue Function
T112	Date 639 650	Actualmente
T113	LIVB 727 736	pacientes
#101	AnnotatorNotes T113	C0030705; Patients; Patient or Disabled Group
T115	Route 883 887	oral
#102	AnnotatorNotes T115	C1527415; Oral Route of Drug administration; Functional Concept
T116	Route 910 914	oral
#103	AnnotatorNotes T116	C1527415; Oral Route of Drug administration; Functional Concept
T117	PHYS 924 948	metabolismo óseo-mineral
#104	AnnotatorNotes T117	C0596204; bone metabolism; Organ or Tissue Function
T118	LIVB 1045 1054	pacientes
#105	AnnotatorNotes T118	C0030705; Patients; Patient or Disabled Group
T119	Duration 1120 1127	6 meses
T120	LIVB 1149 1158	pacientes
#106	AnnotatorNotes T120	C0030705; Patients; Patient or Disabled Group
T121	LIVB 1204 1213	pacientes
#107	AnnotatorNotes T121	C0030705; Patients; Patient or Disabled Group
T122	Route 1282 1286	oral
#108	AnnotatorNotes T122	C1527415; Oral Route of Drug administration; Functional Concept
T123	Dose 1298 1302	1 μg
T124	Frequency 1302 1306	/día
T125	Dose 1352 1361	1 ampolla
T126	Frequency 1361 1365	/sem
T127	Dose 1367 1375	0,266 mg
T128	Frequency 1375 1379	/sem
T129	Route 1396 1404	vía oral
#109	AnnotatorNotes T129	C1527415; Oral Route of Drug administration; Functional Concept
T130	Duration 1419 1426	3 meses
T131	Duration 1556 1567	3 meses más
T132	Duration 1585 1596	los 6 meses
T133	LIVB 1710 1719	pacientes
#110	AnnotatorNotes T133	C0030705; Patients; Patient or Disabled Group
T134	PHYS 2126 2141	eritropoyéticos
#111	AnnotatorNotes T134	C0014819; Erythropoiesis; Organ or Tissue Function
T136	LIVB 2289 2298	pacientes
#112	AnnotatorNotes T136	C0030705; Patients; Patient or Disabled Group
T137	Route 2381 2385	oral
#113	AnnotatorNotes T137	C1527415; Oral Route of Drug administration; Functional Concept
T138	Neg_cue 2415 2418	sin
T139	Duration 2474 2485	los 6 meses
T140	Duration 2519 2530	los 3 meses
T141	Duration 2625 2636	los 3 meses
T148	PHYS 3546 3563	remodelación ósea
#114	AnnotatorNotes T148	C0085268; Bone remodeling; Organ or Tissue Function
T114	Dose 1382 1390	16.000 U
T150	Duration 1666 1684	los meses 0, 3 y 6
T135	Duration 2758 2768	tercer mes
T142	PHYS 1818 1833	remodelado óseo
#115	AnnotatorNotes T142	C0085268; Bone remodeling; Organ or Tissue Function
A1	Assertion T63 Negated
T143	Quantifier_or_Qualifier 13 18	doble
#116	AnnotatorNotes T143	C0205173; Double (qualifier value); Functional Concept
R1	Has_Quantifier_or_Qualifier Arg1:T53 Arg2:T143	
R2	Used_for Arg1:T2 Arg2:T53	
R3	Combined_with Arg1:T2 Arg2:T3	
T144	PHYS 61 74	biomarcadores
R4	Location_of Arg1:T4 Arg2:T104	
R7	Overlap Arg1:T144 Arg2:T104	
#117	AnnotatorNotes T80	C0042870; Vitamin D Deficiency; Disease or Syndrome
R8	Overlap Arg1:T80 Arg2:T7	
R9	Experiences Arg1:T109 Arg2:T80	
R10	Experiences Arg1:T109 Arg2:T7	
R11	Experiences Arg1:T109 Arg2:T9	
R12	Experiences Arg1:T109 Arg2:T10	
R13	Experiences Arg1:T109 Arg2:T11	
R14	Experiences Arg1:T109 Arg2:T82	
R15	Overlap Arg1:T7 Arg2:T9	
R16	Overlap Arg1:T80 Arg2:T9	
R17	Overlap Arg1:T80 Arg2:T10	
R18	Overlap Arg1:T7 Arg2:T10	
T145	Observation 362 377	morbimortalidad
T146	PROC 409 424;435 443	Niveles séricos de 25OHD
#118	AnnotatorNotes T146	C2229552; serum 25-hydroxycholecalciferol measurement; Laboratory Procedure
T147	Quantifier_or_Qualifier 425 434	adecuados
#119	AnnotatorNotes T147	C0205411; Adequate; Qualitative Concept
R19	Has_Quantifier_or_Qualifier Arg1:T146 Arg2:T147	
T151	Observation 544 564	efectos beneficiosos
R20	Causes Arg1:T146 Arg2:T151	
R21	Causes Arg1:T16 Arg2:T151	
R22	Causes Arg1:T83 Arg2:T151	
R23	Location_of Arg1:T18 Arg2:T111	
R24	Location_of Arg1:T20 Arg2:T84	
R26	Overlap Arg1:T151 Arg2:T84	
R27	Experiences Arg1:T113 Arg2:T107	
R28	Experiences Arg1:T113 Arg2:T21	
R30	Experiences Arg1:T113 Arg2:T85	
R31	Used_for Arg1:T22 Arg2:T24	
R32	Used_for Arg1:T25 Arg2:T24	
R33	Combined_with Arg1:T25 Arg2:T28	
R34	Has_Route_or_Mode Arg1:T25 Arg2:T115	
R35	Combined_with Arg1:T25 Arg2:T27	
R36	Has_Route_or_Mode Arg1:T27 Arg2:T116	
R38	Location_of Arg1:T26 Arg2:T117	
T152	Quantifier_or_Qualifier 1001 1006	único
R40	Has_Quantifier_or_Qualifier Arg1:T31 Arg2:T152	
R41	Experiences Arg1:T118 Arg2:T86	
R42	Experiences Arg1:T118 Arg2:T31	
R43	Experiences Arg1:T118 Arg2:T108	
R44	Experiences Arg1:T118 Arg2:T30	
R45	Experiences Arg1:T118 Arg2:T117	
R46	Experiences Arg1:T118 Arg2:T24	
R47	Has_Route_or_Mode Arg1:T22 Arg2:T115	
R50	Has_Duration_or_Interval Arg1:T33 Arg2:T119	
R51	Experiences Arg1:T120 Arg2:T87	
R53	Before Arg1:T1 Arg2:T35	
R54	Used_for Arg1:T88 Arg2:T35	
R55	Has_Route_or_Mode Arg1:T88 Arg2:T122	
R56	Has_Dose_or_Strength Arg1:T88 Arg2:T123	
R57	Has_Frequency Arg1:T88 Arg2:T124	
R58	Experiences Arg1:T121 Arg2:T35	
R59	Used_for Arg1:T36 Arg2:T32	
R60	Has_Dose_or_Strength Arg1:T36 Arg2:T125	
R62	Has_Frequency Arg1:T36 Arg2:T126	
R63	Has_Dose_or_Strength Arg1:T36 Arg2:T127	
R64	Has_Frequency Arg1:T36 Arg2:T128	
R65	Has_Dose_or_Strength Arg1:T36 Arg2:T114	
R66	Has_Route_or_Mode Arg1:T36 Arg2:T129	
R67	Has_Duration_or_Interval Arg1:T37 Arg2:T130	
R68	Used_for Arg1:T38 Arg2:T37	
R69	Overlap Arg1:T38 Arg2:T130	
R70	Overlap Arg1:T39 Arg2:T130	
R71	Used_for Arg1:T39 Arg2:T37	
R72	Has_Duration_or_Interval Arg1:T40 Arg2:T131	
R73	Used_for Arg1:T38 Arg2:T40	
R74	Used_for Arg1:T39 Arg2:T40	
R75	Has_Duration_or_Interval Arg1:T41 Arg2:T132	
R77	Overlap Arg1:T40 Arg2:T41	
R80	Overlap Arg1:T42 Arg2:T150	
#120	AnnotatorNotes T42	C0002778; Analysis of substances; Laboratory Procedure (?) | C0022885; Laboratory Procedures; Laboratory Procedure (?)
R81	Experiences Arg1:T133 Arg2:T42	
R82	Location_of Arg1:T43 Arg2:T34	
R83	Location_of Arg1:T43 Arg2:T90	
R84	Location_of Arg1:T43 Arg2:T91	
R85	Location_of Arg1:T43 Arg2:T92	
R86	Location_of Arg1:T43 Arg2:T93	
R87	Experiences Arg1:T133 Arg2:T34	
R88	Experiences Arg1:T133 Arg2:T90	
R89	Experiences Arg1:T133 Arg2:T91	
R90	Experiences Arg1:T133 Arg2:T92	
R91	Experiences Arg1:T133 Arg2:T93	
R92	Location_of Arg1:T48 Arg2:T142	
R93	Location_of Arg1:T48 Arg2:T23	
R94	Experiences Arg1:T133 Arg2:T23	
R95	Experiences Arg1:T133 Arg2:T49	
R96	Experiences Arg1:T133 Arg2:T50	
R97	Experiences Arg1:T133 Arg2:T17	
R98	Experiences Arg1:T133 Arg2:T44	
R99	Experiences Arg1:T133 Arg2:T45	
R100	Experiences Arg1:T133 Arg2:T54	
R101	Experiences Arg1:T133 Arg2:T55	
R102	Experiences Arg1:T133 Arg2:T56	
#121	AnnotatorNotes T50	C1562880; Procollagen type I amino-terminal propeptide level; Laboratory Procedure
#122	AnnotatorNotes T17	C1562880; Procollagen type I amino-terminal propeptide level; Laboratory Procedure
#123	AnnotatorNotes T44	C2825912; Type I Collagen C-Telopeptide Measurement; Laboratory Procedure 
#124	AnnotatorNotes T46	C3699669; Erythropoiesis assessment; Laboratory Procedure (?)
#125	AnnotatorNotes T47	C3699669; Erythropoiesis assessment; Laboratory Procedure (?)
R103	Experiences Arg1:T136 Arg2:T96	
R104	Used_for Arg1:T62 Arg2:T97	
R105	Has_Route_or_Mode Arg1:T62 Arg2:T137	
T153	Quantifier_or_Qualifier 2386 2393	aislado
R106	Has_Quantifier_or_Qualifier Arg1:T62 Arg2:T153	
R108	Negation Arg1:T138 Arg2:T63	
R110	Overlap Arg1:T63 Arg2:T139	
R111	Overlap Arg1:T63 Arg2:T140	
R112	Used_for Arg1:T99 Arg2:T64	
R113	Overlap Arg1:T66 Arg2:T141	
T154	Observation 2565 2571;2595 2613	reduce los niveles de PTH
#126	AnnotatorNotes T154	C1855803; Decreased or low-normal serum parathyroid hormone (PTH); Finding
R114	Causes Arg1:T64 Arg2:T154	
R115	Overlap Arg1:T154 Arg2:T141	
T155	Neg_cue 2649 2651	no
T156	CONC 2670 2683	significación
#127	AnnotatorNotes T156	C0237881; Statistical Significance; Quantitative Concept (?)
R116	Negation Arg1:T155 Arg2:T156	
A2	Assertion T156 Negated
T157	Observation 2695 2713	descenso de la PTH
#128	AnnotatorNotes T157	C1855803; Decreased or low-normal serum parathyroid hormone (PTH); Finding
R117	Causes Arg1:T64 Arg2:T157	
R118	Overlap Arg1:T157 Arg2:T135	
R119	Overlap Arg1:T67 Arg2:T135	
R120	Location_of Arg1:T69 Arg2:T59	
T158	Neg_cue 2849 2852	sin
T159	CONC 2859 2866	cambios
A3	Assertion T159 Negated
#129	AnnotatorNotes T159	C0443172; Changed status; Quantitative Concept
R121	Negation Arg1:T158 Arg2:T159	
T160	Quantifier_or_Qualifier 2853 2858	otros
A4	Assertion T160 Negated
R122	Negation Arg1:T158 Arg2:T160	
T161	Observation 2891 2897	efecto
A5	Assertion T161 Speculated
#130	AnnotatorNotes T161	C1518681; Outcome of Therapy; Finding (?)
T162	Spec_cue 2883 2890	posible
R123	Speculation Arg1:T162 Arg2:T161	
R124	Before Arg1:T70 Arg2:T159	
R125	Before Arg1:T70 Arg2:T161	
T163	Quantifier_or_Qualifier 2898 2905	directo
A6	Assertion T163 Speculated
R126	Has_Quantifier_or_Qualifier Arg1:T161 Arg2:T163	
R127	Location_of Arg1:T72 Arg2:T161	
R128	Used_for Arg1:T101 Arg2:T60	
R129	Used_for Arg1:T73 Arg2:T60	
T164	Observation 3029 3063	disminución en los niveles de IL-8
R130	Causes Arg1:T60 Arg2:T164	
T165	Observation 3152 3161	respuesta
#131	AnnotatorNotes T165	C1319171; Medication response; Finding
T166	Quantifier_or_Qualifier 3146 3151	mejor
R133	Has_Quantifier_or_Qualifier Arg1:T165 Arg2:T166	
#132	AnnotatorNotes T166	C0332272; Better; Qualitative Concept
R135	Overlap Arg1:T165 Arg2:T68	
T167	Observation 3202 3228	descenso de la inflamación
R136	Before Arg1:T68 Arg2:T167	
T168	Spec_cue 3176 3183	posible
T169	CONC 3184 3192	relación
A7	Assertion T169 Speculated
R137	Speculation Arg1:T168 Arg2:T169	
T170	Neg_cue 3245 3247	no
T171	CONC 3248 3254	cambió
A8	Assertion T171 Negated
#133	AnnotatorNotes T171	C0443172; Changed status; Quantitative Concept
R140	Negation Arg1:T170 Arg2:T171	
T172	Neg_cue 3317 3319	no
T173	CONC 3328 3336	concluir
A9	Assertion T173 Negated
#134	AnnotatorNotes T173	C1707478; Conclusion; Idea or Concept
R141	Negation Arg1:T172 Arg2:T173	
R142	Combined_with Arg1:T77 Arg2:T78	
T174	CONC 3389 3397	ventajas
A10	Assertion T174 Negated
R143	Negation Arg1:T172 Arg2:T174	
T175	Quantifier_or_Qualifier 3503 3507	solo
R146	Has_Quantifier_or_Qualifier Arg1:T79 Arg2:T175	
T176	Observation 3522 3528	efecto
T177	Observation 3407 3413	efecto
#135	AnnotatorNotes T177	C1518681; Outcome of Therapy; Finding (?)
R147	Causes Arg1:T77 Arg2:T177	
R148	Causes Arg1:T78 Arg2:T177	
#136	AnnotatorNotes T176	C1518681; Outcome of Therapy; Finding (?)
T178	Quantifier_or_Qualifier 3529 3536	directo
R149	Has_Quantifier_or_Qualifier Arg1:T176 Arg2:T178	
R151	Location_of Arg1:T103 Arg2:T148	
R152	Before Arg1:T79 Arg2:T176	
A11	Assertion T176 Speculated
T179	Spec_cue 3509 3515	parece
R153	Speculation Arg1:T179 Arg2:T176	
R154	Location_of Arg1:T13 Arg2:T145	
R155	Location_of Arg1:T14 Arg2:T145	
#138	AnnotatorNotes T144	C0005516; Biological Markers; Clinical Attribute
T181	Quantifier_or_Qualifier 3255 3277	de forma significativa
A12	Assertion T181 Negated
#139	AnnotatorNotes T181	C0237881; Statistical Significance; Quantitative Concept
R156	Has_Quantifier_or_Qualifier Arg1:T171 Arg2:T181	
R157	Negation Arg1:T170 Arg2:T181	
R158	Has_Quantifier_or_Qualifier Arg1:T159 Arg2:T160	
#137	AnnotatorNotes T151	C4049461; Unexpected beneficial therapeutic response; Finding (?)
#140	AnnotatorNotes T153	C0205171; Singular; Quantitative Concept
#141	AnnotatorNotes T160	C0205394; Other; Qualitative Concept
#142	AnnotatorNotes T163	C1947931; Direct (qualifier); Qualitative Concept
R5	Overlap Arg1:T60 Arg2:T165	
#143	AnnotatorNotes T169	C0332281; Associated with; Qualitative Concept
#144	AnnotatorNotes T178	C1947931; Direct (qualifier); Qualitative Concept
#145	AnnotatorNotes T152	C0205171; Singular; Quantitative Concept
#146	AnnotatorNotes T175	C0205171; Singular; Quantitative Concept
#147	AnnotatorNotes T112	C0521116; Current (present time); Temporal Concept
A13	Experiencer T133 Patient
A14	Experiencer T136 Patient
A15	Experiencer T121 Patient
A16	Experiencer T120 Patient
A17	Experiencer T118 Patient
A18	Experiencer T113 Patient
A19	Experiencer T109 Patient
R6	Has_Result_or_Value Arg1:T66 Arg2:T154	
R25	Has_Result_or_Value Arg1:T67 Arg2:T157	
R29	Has_Result_or_Value Arg1:T89 Arg2:T164	
